Clinical Trial Update: Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update on entinostat in pediatric patients with recurrent or refractory solid tumors, completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Stem Neoplasm
• Central Nervous System Neoplasm
• Lymphomas
• Malignant Solid Neoplasm
• Pineal Region Neoplasm
• Visual Pathway Glioma

Drugs mentioned

• Entinostat (entinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Brain Stem Neoplasm, Pineal Region Neoplasm | Phase 1 | Status: COMPLETED | Results posted: 2023-01-31